0001062993-24-005756.txt : 20240306 0001062993-24-005756.hdr.sgml : 20240306 20240306193834 ACCESSION NUMBER: 0001062993-24-005756 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240125 FILED AS OF DATE: 20240306 DATE AS OF CHANGE: 20240306 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: BOBULSKY SUSAN CENTRAL INDEX KEY: 0001820885 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38957 FILM NUMBER: 24727752 MAIL ADDRESS: STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION STREET 2: 1551 EASTLAKE AVE E STE 200 CITY: SEATTLE STATE: WA ZIP: 98102 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp CENTRAL INDEX KEY: 0001478320 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 270907024 STATE OF INCORPORATION: WA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 BUSINESS PHONE: 206-659-0067 MAIL ADDRESS: STREET 1: 1165 EASTLAKE AVE E CITY: SEATTLE STATE: WA ZIP: 98109 FORMER COMPANY: FORMER CONFORMED NAME: Adaptive TCR Corp DATE OF NAME CHANGE: 20091209 3 1 form3.xml INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES X0206 3 2024-01-25 0 0001478320 Adaptive Biotechnologies Corp ADPT 0001820885 BOBULSKY SUSAN C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION 1165 EASTLAKE AVENUE EAST SEATTLE WA 98109 0 1 0 0 Chief Commercial Officer, MRD Common Stock 128302 D Stock Option (Right to Buy) 1.98 2024-10-13 Common Stock 5000 D Stock Option (Right to Buy) 6.27 2027-04-25 Common Stock 20000 D Stock Option (Right to Buy) 6.55 2028-04-24 Common Stock 28750 D Stock Option (Right to Buy) 28.32 2030-02-27 Common Stock 13474 D Stock Option (Right to Buy) 39.50 2030-08-13 Common Stock 20000 D Stock Option (Right to Buy) 43.68 2031-03-04 Common Stock 22894 D Stock Option (Right to Buy) 12.14 2032-03-04 Common Stock 102965 D Stock Option (Right to Buy) 8.46 2033-03-06 Common Stock 88689 D The options are fully exercisable. The options will vest with respect to 1/4 of such shares on February 27, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options will vest with respect to 1/4 of such shares on August 6, 2021, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options will vest with respect to 1/4 of such shares on March 4, 2022, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options will vest with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. The options will vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested. /s/ Susan Bobulsky by Stacy L. Taylor, Attorney-in-Fact 2024-03-06